Entities

Eric Elenko PhD is PureTech’s co-founder and its published acting CEO of Gallop Oncology. His work includes discovery, fundraising and co-founding Seaport Therapeutics, with contributions to programs that became EndeavorRx, Plenity and Cobenfy. Previously a McKinsey consultant, he studied biology at Swarthmore and biomedical sciences at UC San Diego.

Landhing Moran is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Center for Clinical Trials Network. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Michael Inbar CPA MBA is PureTech’s chief accounting officer, overseeing accounting, compliance and finance operations. He joined in 2023 after CFO roles at Acronis and Wallarm, with earlier experience at Solid Biosciences, Syros, GlassHouse and EY. His published biography describes more than 20 years in accounting and finance.

Richard Jenkins is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Epidemiology, Services and Prevention Research. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Sheba Dunston is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Epidemiology, Services and Prevention Research. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Kiran Vemuri is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Neuroscience and Behavior. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Robert Lyne is PureTech Health’s CEO and board director, appointed permanently on December 18, 2025 after serving as interim CEO since July 2025. He previously led Arix Bioscience and worked at Touchstone Innovations and Bird & Bird. He holds degrees from Oxford and Oxford Brookes; PureTech reports his involvement in more than 80 venture financings.

PureTech Health is a Boston-based biotherapeutics and company-creation business operating through UK public parent PureTech Health plc and its wholly owned Delaware subsidiary PureTech Health LLC. The SEC history identifies predecessor operations and an initial financing greater than USD5M in2004; the plc was incorporated May8,2015 and acquired its predecessor in the June2015 IPO reorganization. It develops therapeutic programs and forms separately financed Founded Entities, retaining equity, royalties and contractual milestone rights. Relevant neuroscience programs include cognitive digital therapeutics at Akili, Karuna’s muscarinic schizophrenia treatment Cobenfy and Seaport’s Glyph platform for neuropsychiatric medicines. Its broader research spans drug delivery, immunology, fibrosis and oncology. The published sources support neuroscience and biotechnology relevance; they do not establish PureTech as a generative-AI model company. Its current public roster identifies CEO Robert Lyne, appointed permanently December18,2025; earlier Daphne Zohar/Bharatt Chowrira CEO roles are historical. Scientific collaborators are external academic/industry affiliations rather than an employee list. PureTech maintains its primary London Stock Exchange listing; in April2026 it announced voluntary Nasdaq ADS delisting and a planned transition to an OTC ADR program, with execution details source-qualified rather than assuming continued Nasdaq listing. SEC2025 financial statements document actual parent IPO gross proceedsUSD171M plus25M over-allotment in2015, and approximately100M gross placing in2018. Parent cash balances, amounts raised by Founded Entities, royalty monetization proceeds, acquisition exits and contingent licensing milestones are not new parent equity financings or LP-fund closes. This is a corporate issuer and venture creator, not a standalone private VC fund. Akili2016 financing was received in tranches; parent annuals confirm42.4M total actualAkili financings thatyear with25M fromPureTech, distinct from PureTech’s own capital raises.

John Satterlee is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Neuroscience and Behavior. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Holly Moore is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Neuroscience and Behavior. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Sunila Nair is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Neuroscience and Behavior. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Yu Lin is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Neuroscience and Behavior. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Guifang Lao is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Therapeutics and Medical Consequences. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Kathleen Borgmann is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Neuroscience and Behavior. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Mary Kautz is named by the National Institute on Drug Abuse as DNB lead, Tobacco Regulatory Science Program. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Raul Mandler is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Therapeutics and Medical Consequences. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Boris Sabirzhanov is named by the National Institute on Drug Abuse as OTIPI SBIR/STTR programme staff — HEAL Initiative. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Ernestine Lenteu is named by the National Institute on Drug Abuse as Program Specialist, OTIPI. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Jonathan Pollock is named by the National Institute on Drug Abuse as Director, Genetics, Epigenetics and Development Branch. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Shang-Yi Tsai is named by the National Institute on Drug Abuse as Director, Integrative Neuroscience Branch (Anne Tsai). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Subramaniam Ananthan is named by the National Institute on Drug Abuse as Director, Chemistry Pharmacology Branch (Sam Ananthan). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Tam Nguyen is named by the National Institute on Drug Abuse as OTIPI SBIR/STTR programme staff — pharmacotherapeutic and translational research. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Vani Pariyadath is named by the National Institute on Drug Abuse as Director, Behavioral Cognitive Neuroscience Branch. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Jessica Lukacs is named by the National Institute on Drug Abuse as OTIPI SBIR/STTR programme staff — business development (published Jess Lukacs). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Sara Lioi is named by the National Institute on Drug Abuse as OTIPI translational initiatives staff — drug discovery, challenges and prizes. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Saravanan Karuppagounder is named by the National Institute on Drug Abuse as OTIPI SBIR/STTR programme staff — therapeutics and biomarkers. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Yordan Kostov is named by the National Institute on Drug Abuse as OTIPI SBIR/STTR programme staff — diagnostics and medical devices. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Elena Koustova is named by the National Institute on Drug Abuse as Director, OTIPI; Principal Small Business Program Manager. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Leonardo Angelone is named by the National Institute on Drug Abuse as OTIPI medical devices programme; NIH Blueprint Medtech programme lead. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Morris Flood is named by the National Institute on Drug Abuse as OTIPI SBIR/STTR programme staff — research tools, wellness and training. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Rachel Kelley is named by the National Institute on Drug Abuse as Scientific Program Analyst, HEAL Initiative Research Program. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Aminul Islam is named by the National Institute on Drug Abuse as Health Scientist Administrator, HEAL Initiative Research Program. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Amy Goldstein is named by the National Institute on Drug Abuse as Chief, Prevention Research Branch. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Michele Rankin is named by the National Institute on Drug Abuse as Director, HEAL Initiative Research Program. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Shannon Mitchell is named by the National Institute on Drug Abuse as Deputy Chief, Prevention Research Branch. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Shelly Su is named by the National Institute on Drug Abuse as Deputy Chief, Treatment and Recovery Services Research Branch. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Bethany Deeds is named by the National Institute on Drug Abuse as Deputy Director, Division of Epidemiology, Services and Prevention Research. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Carlos Blanco is named by the National Institute on Drug Abuse as Director, Division of Epidemiology, Services and Prevention Research. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Marie Lafontant is named by the National Institute on Drug Abuse as Staff Assistant to the Associate Director for Management. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Marsha Lopez is named by the National Institute on Drug Abuse as Chief, Epidemiology Research Branch. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

MeLisa Creamer is named by the National Institute on Drug Abuse as Deputy Chief, Epidemiology Research Branch. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Monglan Le is named by the National Institute on Drug Abuse as Correspondence Systems Coordinator. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Tisha Wiley is named by the National Institute on Drug Abuse as Chief, Treatment and Recovery Services Research Branch. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Ellie Johnson is named by the National Institute on Drug Abuse as Supervisory Staff Assistant. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Hilda Schulke is named by the National Institute on Drug Abuse as Staff Assistant to the Director. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Nathaniel Davis is named by the National Institute on Drug Abuse as Executive Officer. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Poorti Khosla is named by the National Institute on Drug Abuse as Staff Assistant to the Deputy Director. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Shkeda Johnson-Young is named by the National Institute on Drug Abuse as Deputy Executive Officer. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Thomas Clarke is named by the National Institute on Drug Abuse as Chief of Staff (published as Tom Clarke). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Wilson M. Compton, M.D., M.P.E., is NIDA deputy director. His official biography describes scientific leadership over NIDA’s research portfolio, prevention, treatment and health consequences of drug use. He previously directed the Division of Epidemiology, Services and Prevention Research from 2002 to 2013. Current directorate listings and 2026 council material corroborate this institutional role; no personal company investment is inferred.

Nora D. Volkow, M.D., is the director of NIDA. Her official biography describes a research psychiatrist and brain-imaging scientist whose work helped establish drug addiction as a disease of the brain. She became NIDA director in May 2003. The current official leadership page and May 2026 council minutes verify her ongoing institute leadership. Funding decisions and specific company award amounts are separate from this personnel role.

Roland A. Owens serves as NIH Acting Deputy Director for Intramural Research. This current federal biomedical research agency role is verified by the official NIH leadership directory and individual biography. The agency supports basic, clinical and translational research; a leadership appointment does not establish a personal grant or private-company investment.

Jon R. Lorsch serves as NIH Deputy Director for Extramural Research. This current federal biomedical research agency role is verified by the official NIH leadership directory and individual biography. The agency supports basic, clinical and translational research; a leadership appointment does not establish a personal grant or private-company investment.

Alfred C. Johnson serves as NIH Deputy Director for Management. This current federal biomedical research agency role is verified by the official NIH leadership directory and individual biography. The agency supports basic, clinical and translational research; a leadership appointment does not establish a personal grant or private-company investment.

Nicole C. Kleinstreuer serves as NIH Deputy Director for Program Coordination, Planning, and Strategic Initiatives. This current federal biomedical research agency role is verified by the official NIH leadership directory and individual biography. The agency supports basic, clinical and translational research; a leadership appointment does not establish a personal grant or private-company investment.

Matthew J. Memoli serves as NIH Principal Deputy Director. This current federal biomedical research agency role is verified by the official NIH leadership directory and individual biography. The agency supports basic, clinical and translational research; a leadership appointment does not establish a personal grant or private-company investment.

Jay Bhattacharya serves as NIH Director. This current federal biomedical research agency role is verified by the official NIH leadership directory and individual biography. The agency supports basic, clinical and translational research; a leadership appointment does not establish a personal grant or private-company investment.

The National Institute on Drug Abuse (NIDA) is a United States federal biomedical research institute within the National Institutes of Health, a component of the Department of Health and Human Services. Established in 1974, it advances science on drug use and addiction and applies that knowledge to improve individual and public health. It supports basic and clinical neuroscience, behavioural research, epidemiology, prevention, addiction treatment, brain-development studies, and translation of therapeutics, devices and digital health applications. Nora D. Volkow is the current director and Wilson M. Compton the deputy director according to the official leadership directory and 2026 council material. The institute publishes directorate staff, research programme and division contacts, and a National Advisory Council on Drug Abuse with external advisers. Roles distinguish federal staff, programme contacts and external council members. The Office of Translational Initiatives and Program Innovations coordinates small-business research programmes, including SBIR/STTR mechanisms relevant to AI, biotechnology and neurotechnology. The May 2026 council minutes report an approximately USD 1.66 billion FY2026 operating budget. This is a government institutional budget, not a venture fund close, assets under management or a specific company investment. Proposed reorganizations in presidential budget requests are not treated as completed legal renames: NIDA remains the actual administering and funding institute identified by NIH RePORTER for Tamade LLC/Flowly R44DA049630 and Doro Mind R43DA064245. Recipient grant awards, fiscal years, notice dates and project periods are separately verified by the issuer-profile owners. Grant funding is non-dilutive research support, not automatically priced equity; parent NIH and NIDA are not counted as two independent checks for the same award.

The National Institutes of Health (NIH) is the United States federal biomedical research agency within the Department of Health and Human Services. Its origins trace to the 1887 Hygienic Laboratory; the agency later became the National Institutes of Health. NIH conducts and supports basic, clinical and translational research through its Office of the Director and its institutes and centers. Its mission includes understanding living systems, improving health and reducing illness and disability. Relevant work spans neuroscience, brain research, biotechnology, medical technologies, data science and artificial intelligence. The current official directorate names Jay Bhattacharya, Principal Deputy Director Matthew J. Memoli and deputy directors Nicole C. Kleinstreuer, Alfred C. Johnson, Jon R. Lorsch and acting intramural deputy Roland A. Owens, alongside published associate directors. Roles of NIH institute directors remain differentiated from the central agency directorate. NIDA is a component institute, rather than a second independent parent agency or private venture firm. NIH administers competitive research funding, including SBIR/STTR grants to eligible small businesses. Agency and programme budgets, requested appropriations and competitive award ceilings are distinct from actual recipient awards, private LP commitments and company equity financings. Actual NIDA-funded Flowly/Tamade LLC and Doro Mind projects belong to that identified funding institute; a duplicate parent NIH check is not inferred. Research aims and an award do not establish clinical efficacy or regulatory approval. This institutional investor identity supports source-qualified grant-provider records, not an assertion that NIH is a private investment manager.

OculAudio is developing an eyeglass-based hearing-assistance system that combines directional microphones, digital signal processing and face detection to emphasize the person the user is looking at. Its published design uses a 16-microphone array, two audio processors and Bluetooth-linked wireless earbuds, with proposed app controls for hearing profiles, noise cancellation and remote support. Founded by Tom Austad in 2017, OculAudio AS is a Norwegian hearing-technology company; the published product is described as being developed, without an established commercial availability or clinical-efficacy claim.

Previously an executive vice president for EMEA and APAC at Senzime; published as an associated adviser.

Advises on electrical engineering and software development.

Hearing-industry executive trained in acoustics, with experience at ExSilent, Varibel Innovations and Otoharmonics.

University of Oslo physician and professor.

Published on the company website as Jon H Ulvensøen; the official register gives Jon Herman Ulvensøen.

Physician and professor, published on MedStorm’s advisory board.

Professor in electrical engineering, media and computer science, published as an associated adviser.

The company website lists him as chairman, but the current official registry names Tom Austad instead. This published affiliation does not establish a current directorship.

The company website lists him as director, but he is absent from the current official company register. Current tenure is unconfirmed.

Uppsala University neonatal intensive-care physician and professor.

Engineer with training at the Norwegian University of Science and Technology and Norwegian School of Economics.

Published on the company website as Thorvald Steen; the official register gives Thorvald Helmen Steen.

Norwegian entrepreneur who founded OculAudio in 2017; experienced in telecommunications business development. The official current registry lists him as board chairman, superseding the differing chairman shown on the undated company team page.

Advises on regulatory technical issues and regulatory affairs.

OculAudio publishes the title CSMFO without expanding the acronym.

Quality auditor experienced in ISO, GMP, HACCP and quality assurance.

MedStorm Innovation develops medical instruments that monitor pain and nociception using skin conductance. Its wearable Pain-Nociceptive Sensor measures changes in sweating driven by sympathetic nerve activity and applies signal-processing algorithms to help clinicians assess responses to painful stimuli, awakening and nerve blocks. The system supports use during anesthesia and postoperative care, neonatal monitoring and veterinary applications, with connectivity to Philips and Masimo monitors and HL7 clinical information systems. Med-Storm Innovation AS is the Norwegian legal company behind the MedStorm brand.

Engineer working on software and technical development.

Physician and University of Oslo researcher who invented MedStorm’s skin-conductance approach to pain and nociception assessment.

Published by MedStorm as Jens Gran; the official registry gives Jens Otto Gran. Civil engineer with finance training and experience in product development, entrepreneurship and project financing.

Brainworks Ventures backs early-stage companies built around artificial intelligence, including enterprise software, developer infrastructure, health and biotechnology, brain-machine interfaces and creative media. Its partners combine technical diligence with company-building support and use AI in investment operations, sourcing opportunities globally with European coverage led by Volker Hirsch.

Tianjin HY Asset Management Co., Ltd. (天津合盈资产管理有限公司), also known as Heying Capital, invests in private companies and manages industry-focused investment vehicles. Its activities include equity investing, industrial funds and acquisition restructuring, with a brain-computer-interface strategy supporting the commercialization of neurological diagnostics, neuromodulation and neural-interface technologies through collaboration with the Haihe Laboratory and regional industrial partners.

Venture investor with prior experience at Forté Ventures and Siemens Venture Capital.

AI technologist and entrepreneur; previously a DARPA Biological Technologies Office program manager and founder of MobiTV and MicroDisplay Corporation.

QurieGen develops single-cell multi-omics technology and AI models that help pharmaceutical and biotechnology companies understand disease mechanisms and predict how cells respond to drugs. Its QuRIE-seq platform measures RNA and multiple protein signals within the same cell over time, generating experimental data for AI Virtual Cell models. The Radboud University spin-off combines laboratory experiments with computational modelling to identify targets, explain drug responses and reduce uncertainty in drug discovery.

VitalSigns develops a connected diagnostic device that captures several biosignals during one physical examination, including ECG, blood pressure, oxygen saturation, temperature, respiratory rate and heart and lung sounds. It combines these measurements with automatic documentation and AI analysis to support clinicians and simplify primary-care and remote examinations. The Espoo-based company spun out of an Aalto University research project and is developing a diagnostic-support business built around its device and clinical datasets.

Steven Ju is a head of legal at Sazze Partners, according to the manager’s current public operations team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Hyeseong Lee is a assistant manager at Sazze Partners, according to the manager’s current public operations team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Blaire Yoo is a manager at Sazze Partners, according to the manager’s current public operations team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Jinlee Ok is a senior manager at Sazze Partners, according to the manager’s current public operations team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Gihun Choi is a associate at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Grace Kim is a associate at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Ukjin (Jay) Kwon is a principal at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Kathy Ku is a partner at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Ohsang Kwon is a partner at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Do Gyun Guen is a partner at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Sukhyun Kim is a venture partner at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea. The public website labels his affiliation Venture Partner; the April2026 adviser filing separately lists Sukhyun Kim as managing partner, status acquired October2021. These differing primary-source labels are retained without inferring employment or a departure date.

Eun Soo Park is a partner at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Greg Kwangrog Kim is a partner at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea. The April2026 adviser filing names Kwangrog Kim CFO and managing partner, with the status acquired inJune2018; the FundII SEC filing gives the full name Greg Kwangrog Kim.

Kiha Lee is a partner at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea. The April2026 adviser filing additionally names Kiha Lee CEO and managing partner, with the status acquired inJune2018.

Sazze Partners is the US–Korea venture manager formerly named Primer Sazze Partners, operating at sazze.vc. It invests from early stage through growth follow-ons and supports cross-border expansion, go-to-market work, fundraising, board development and executive recruitment. Its published portfolio includes artificial intelligence, AI infrastructure, robotics, clean technology and digital healthcare companies. The legal adviser is Sazze Partners, Inc., SEC exempt reporting adviser CRD298152 / file802-132603, a Delaware corporation established in2018; the former Primer Sazze Partners, Inc. name belongs to this same entity. The separate Korean Primer accelerator and operating company Sazze, Inc. are not merged into this manager. Fund sold amounts are dated regulatory subscription snapshots, rather than total manager AUM or final-close claims.

Geunbae Jang is an independent director of SKNetworks, named in its current official governance directory with a March2025 appointment month. The company’s biography identifies him as an accounting professor at HandongGlobalUniversity and describes finance, strategy and advisory experience at DoosanBobcat, construction-equipment finance leadership at DoosanInfracore and AsiaPacific financial-control work at eBay. He serves on SKNetworks’ human-resources committee, contributing finance and accounting oversight. No company operating investment title or personal subscription is inferred.

Healthcare investment group providing family-office and growth capital to emerging companies developing medicines, medical devices, health technology and healthcare services. Its executives combine clinical experience with investment evaluation, financial strategy and company-building support. The firm participated in Anodyne Nanotech’s 2026 Series A for a microneedle patch that delivers biologic medicines through the skin, and in OrphoMed’s 2017 financing for gastrointestinal drug development.

Athens-based venture capital firm supporting Greek technology founders at pre-seed and seed stages as they build businesses for international markets. It invests across sectors, including AI, advanced materials and medical devices, and helps founders with market validation, operations and subsequent fundraising. The firm publishes initial investments of up to €500,000, followed by support in later rounds. Velocity belongs to the EquiFund-supported venture ecosystem and led Anodyne Nanotech’s June 2026 Series A. Its portfolio includes drug-delivery technology, Parkinson’s monitoring and AI-assisted pharmaceutical research.

Healthcare investor, strategist and operator focused on biopharmaceuticals, medical devices, services and technology. He evaluates and manages healthcare investments and advises companies on financing, strategy and product development. Previously he led Parsolex GMP Center and he serves as vice chair of the CUNY School of Public Health Foundation.

Greek venture investor who launched Velocity Partners in 2018, co-founded Found.ation and SocialInnov, and founded TEDxAthens. He is also a founding partner of the separate Apeiron Ventures firm.

Physician and healthcare investor leading Relativity Healthcare Partners. He serves on Ansun Biopharma’s board and has worked with emerging drug and medical-device companies. His medical training includes an MD at UC Irvine and biology studies at the University of Pennsylvania.

Healthy Young Minds (HYM) is a US pediatric behavioral-health and developmental-care business offering multidisciplinary teletherapy, psychological assessments, counseling, art therapy, speech and language therapy, occupational therapy and autism/ADHD support. Founder and CEO Paul Graf developed its care model after earlier work at Vail Mind Center and the clinic’s transition to remote care during COVID-19. The company emphasizes access for Medicaid families and uses care plans and progress measures to coordinate clinicians across disciplines. Its public brand profile identifies Denver headquarters and multiple US service locations. Public primary sources identify chief therapeutic officer Julie Norman, neuropsychology leader Cari Whitlock, COO Jonathan Shambroom and additional source-qualified clinical affiliations. CMS NPPES records associate the HYM brand and Paul Graf with Healthy Young Minds 2 LLC and several state provider entities; their exact corporate ownership structure is not independently established here. Howdy Partners, formerly Greater Colorado Venture Fund, and Hopelab identify HYM in their investment portfolios, without public individual allocation, investment date or priced-round terms. Reported cumulative financing, fundraising targets and pitch competition wins are distinguished from completed equity rounds. This company is distinct from Australian, UK NHS, Norfolk charitable and Glasgow programmes with similar names. No autonomous AI-treatment claim is made.

Angela Fontenot is named in Healthy Young Minds’ public employee listing, and her own professional profile identifies the company as her affiliation. Her exact job title and detailed current responsibilities are not published in the accessible primary sources.

Cari Whitlock, PsyD, leads pediatric psychologists at Healthy Young Minds. Her specialties include pediatric neuropsychology, trauma and forensic evaluations. She has trained psychologists and social workers through Department of Defense and VA work, cared for children with neurological conditions and researched ADHD.

Jonathan Shambroom is Healthy Young Minds’ COO, identified in his Supernova founder-community biography and corroborated by his own current professional profile and HYM employee listing. He has held operating and product leadership roles at technology startups and worked in seed investment operations.

Julie D’Orsi is identified in Healthy Young Minds’ published educational articles as lead psychometrist, discussing psychological evaluations, executive function and school accommodations. The company’s current public LinkedIn employee listing also names her. No full appointment date is disclosed.

Julie Norman is identified on Healthy Young Minds’ current speech and language therapy page as chief therapeutic officer. A speech-language pathologist, she was described as a lead therapist in earlier HYM educational articles. No exact promotion date is published.

Michael Kornberg, MD, is identified by Healthy Young Minds as a child and adolescent psychiatrist in its published educational material on social-skills groups. His clinical affiliation is recorded with that source; a complete current appointment or employment history is not publicly established.

Michelle Floyd-Rebollo, MD, is a pediatrician with United States and Spain experience, integrative-health training and interests in child development and mental health. HYM names her in its employee listing, and her own 2025 post describes presenting HYM teletherapy outcome data. Her current principal clinic biography is at Empower U; an undated third-party HYM medical-director title is not treated as confirmed current employment.

Michelle L. Zube, MA, BCBA, is identified in HYM educational articles as behavioral therapy lead. A 2022 professional event biography describes licensed behavior-analysis and teaching qualifications, telehealth, parent training and Acceptance and Commitment Training. Current tenure beyond the live published affiliation is not independently dated.

Paul Graf is the founder and CEO of Healthy Young Minds. His earlier technology entrepreneurship and investment work preceded founding Vail Mind Center in Edwards, Colorado. Experience shifting that clinic to teletherapy during COVID-19 inspired HYM’s multidisciplinary pediatric care model and focus on Medicaid access.

Susanne Graf, ATR-BC, LCAT, MFA, leads art therapy at Healthy Young Minds. Her own 2023 Vail board application describes leading its multistate teletherapy art-therapy team and co-founding Vail Mind Center. HYM’s service page spells her first name Susanna; her application and other HYM articles identify Susanne.

AD Mohanraj is vice president of engineering at City Light Capital, as identified in the firm’s current public team directory.

Rohan Nair is head of product at City Light Capital, as identified in the firm’s current public team directory.

Grace Cushman is senior vice president of operations at City Light Capital, as identified in the firm’s current public team directory.

Jeff Rinehart is a partner at City Light Capital. The firm’s current public directory identifies him as one of its two partners; the firm invests in technology-led care, climate and education businesses.

Josh Cohen is a partner and co-founder of City Light Capital, focused on technology investments with measurable social impact. A published2020 Water Innovation Advisors biography describes earlier family-office investing, venture/private-debt work and technology-company business development. Its historical outside board/adviser affiliations are not asserted as current appointments. He is distinct from the later Innovation Endeavors investor also named Josh Cohen.

Hwajin Chang is an independent director of SKNetworks and chair of its human-resources committee. Its own current board biography lists leadership experience including president of APAC at Cohere, president of ConfluentKorea and GoogleCloudKorea, MicrosoftAsiaPacific strategy leadership and CEO/president of IBMKorea. That background supports his technology and AI expertise on the board; previous outside leadership titles are not all treated as simultaneous current positions. The company lists his board appointment month as March2024.

Moonyoung Lee is an independent director of SKNetworks, according to its current governance directory. The company identifies her accounting expertise through an associate professorship at DuksungWomen’sUniversity and public-service experience with the FinancialServicesCommission and Dobong-gu financial-plan deliberations. She participates in the board’s strategy and ESG oversight. The current directory gives an initial2021 appointment and a2024 reappointment month; no undisclosed exact employment day or payroll position is inferred.

Sooil Chai is the independent chair of SKNetworks’ board of directors, as listed in the company’s current public governance directory. He chairs its strategy and ESG committee, overseeing corporate strategy and long-term sustainability alongside the board’s investment and risk responsibilities. The company identifies his earlier professional background in financial-institution work at BostonConsultingGroup in AsiaPacific. The independent board chair role is distinct from the company’s CEO and operational management.

Keedong Kim is a nonexecutive director of SK Networks, named in its current official governance directory and shareholder voting records. The company’s sustainability report identifies his wider professional background in SKInc.finance leadership and previous management-support and finance responsibilities at SKChemicals. His SKNetworks duties include board oversight and membership of its human-resources and strategy/ESG committees. This is a nonexecutive governance appointment, not a claim that he is a full-time SKNetworks investment employee.

Sunghwan Choi is an executive director of SK Networks and is identified in its own2025 AIWAVE announcement as president and chief operating officer. He has presented the company’s AI strategy and led its engagement with global technology and investment partners. The company’s report lists earlier responsibilities in business leadership, planning, the HappinessDesignCenter and strategic planning, along with SKInc.business-model innovation work. His board affiliation is separate from his operating executive capacity and is not evidence of a personal financing ticket.

Hojeong Lee is CEO and president of SK Networks, independently confirmed by the company’s current2026 CEO message and public board directory. He leads the listed operating holding company’s transition toward AI services and strategic portfolio management. Its own sustainability report describes previous responsibilities as president, head of management support and new growth at SKNetworks, and director of InvestmentCenter2 at SKInc. His corporate leadership is distinct from a personal investor identity. The governance page uses several romanisations of his name and includes older appointment metadata; no precise current reappointment or departure day is inferred.

Jonny He, CPA is the CFO named in Eckuity LLC’s March 30, 2026 ADV and Eckuity Capital Management LLC’s April 3, 2026 ADV. His public professional profile republishes Eckuity’s joint CFO/COO appointment. The newer platform directory lists Ken Eagle as CFO and Ryan Green as COO; Jonny’s role is scoped to those dated filings and earlier appointment, with no guessed departure date. His public profile uses a generic avatar, so no substitute portrait is imported.

John Hood is advisory board at Eckuity Capital. Biotechnology entrepreneur and Endeavor BioMedicines co-founder. His Impact Biomedicines transaction included contingent milestones, so its maximum headline value is not treated as closed investment cash.

Vishal Jain co-founded Eckuity with Youssef Sebban according to its February 2024 final-close announcement. The March 30, 2026 Eckuity LLC ADV still lists him as managing partner and control owner. He is absent the newer public platform directory; this does not establish that his Fund I legal position ended. FINRA’s current BrokerCheck reports his Eckuity managing-partner activity since March 2021. Exact employment end date and authentic portrait remain unverified.

Manuel Hidalgo Medina is advisory board at Eckuity Capital. Oncology researcher and public-company director. Bristol Myers Squibb’s 2026 proxy dates his Weill Cornell professorship and division-chief tenure to 2019–2025; Eckuity’s older Cornell headline is qualified accordingly.

Hocine Sidi-Said is advisory board at Eckuity Capital. Healthcare entrepreneur who co-founded KELIX bio; contributes pharmaceutical-platform development and international healthcare experience. Exact current outside executive position is not inferred from an older headline.

Diane Simeone is advisory board at Eckuity Capital. Surgeon-scientist and UC San Diego Moores Cancer Center director contributing oncology research and clinical-development expertise.

Tom Schoenherr is advisory board at Eckuity Capital. Genetics and diagnostics executive associated with Ambry Genetics. Eckuity labels his CEO affiliation historical, while Ambry’s own directory still lists him as CEO; no inferred employment end date is recorded.

Francois Sarkozy is advisory board at Eckuity Capital. Physician and FSNB Health & Care founder contributing healthcare strategy and institutional relationships; distinct from his brother Nicolas Sarkozy.

Daniel Vial is venture partner at Eckuity Capital. Healthcare policy and market-access adviser. This is the pharmaceutical-sector Daniel Vial linked by Eckuity, not the similarly named sports journalist.

Frederic Gilg is venture partner at Eckuity Capital. Healthcare investment and strategy professional associated with GA Partners; contributes operational and market analysis.

Michael Rossbach is venture partner at Eckuity Capital. Genomics scientist and Axiom-Insights founder with experience at the Genome Institute of Singapore and Vela Diagnostics; contributes precision-medicine and diagnostic expertise.

Abderrahim Mahfoudi is venture partner at Eckuity Capital. Biotechnology scientist and research executive contributing therapeutic development and translational-research expertise.

Lokman Ouijdani is venture partner at Eckuity Capital. Healthcare transaction and investment adviser with experience in international strategy and market expansion.

Richard Pasternak is venture partner at Eckuity Capital. Cardiologist and former Merck clinical-development executive contributing cardiovascular therapeutic-development expertise.

Dee Athwal is venture partner at Eckuity Capital. Biologics and antibody-development executive, also known as Diljeet Singh Athwal; Amethyst Pharma publishes his named consultant biography. Eckuity’s Complement CEO headline is older than Complement’s current directory.

Natalya McLane directs product management at Neurala. Her software career spans on-premises products, SaaS and computer vision, including product strategy and coordination across technical teams. She holds bachelor’s and master’s degrees in computer science and has completed additional management coursework.

Larry Florin is venture partner at Eckuity Capital. Clinical-research executive, also known as Lawrence Florin, appointed Hesperos CEO in 2024; contributes drug-development and microphysiological-systems experience.

Jean-Raymond Raynal, also called JR, is an engineering manager at Neurala. Over more than a decade at the company he progressed from engineering intern to leading software teams and building core vision infrastructure. He studied computer science and robotics at ENSEIRB-MATMECA, part of Bordeaux INP.

EarlySight develops retinal imaging hardware and AI analysis tools for ophthalmologists, clinical researchers and pharmaceutical companies. Its Cellularis platform combines adaptive optics with transscleral flood illumination to image retinal structures at cellular resolution, including pigment epithelial cells, photoreceptors and the retinal nerve fibre layer. The resulting images support investigation and monitoring of conditions such as age-related macular degeneration, glaucoma and diabetic retinopathy. The EPFL spinout also develops digital biomarker analysis and collaborates with RetinAI to connect its imaging to automated interpretation and longitudinal disease tracking.

Sarcura develops an instrument platform for automated manufacturing of advanced cell therapies. It combines silicon photonics, semiconductor chips and microfluidic cartridges to detect, sort and manipulate individual cells while measuring and controlling the manufacturing process in real time. Its modular approach aims to shrink production equipment and reduce manual handling in workflows such as CAR-T cell therapy manufacturing. The Austrian company is developing its SiPlex prototype and the broader autonomous manufacturing platform.

Sarcura co-founder and CEO, responsible for company strategy and resources. Previously worked in innovation and business development at GEA, Parker Hannifin and Pall. Holds an MBA in Innovation & Entrepreneurship from WU Executive Academy and an engineering degree in biochemistry, biotechnology and genetics.

Sarcura co-founder and chief scientific officer leading application development. Previously led stem-cell technology research teams at Fraunhofer and worked on cell therapy at GEA. Holds a doctorate from the University of the Saarland medical faculty and a biology diploma from TU Darmstadt.

Named to Sarcura’s advisory board in April 2022. The appointment article describes cell therapy manufacturing and automation work at Takeda, Torque Therapeutics and Novartis, including Kymriah process development. Holds an MIT doctorate in aerospace engineering. These are source-dated career details; continued 2026 advisory tenure is not independently established.

Sarcura CTO leading development of cell and gene therapy manufacturing equipment. Previously worked in research, programs and development at Illumina, Schott and EV Group. Holds an MBA in Biotechnology and Pharmaceutical Management and an engineering degree in chemical engineering.

Named to Sarcura’s advisory board in April 2022. The appointment article describes technical operations and cell and gene therapy leadership at Orchard Therapeutics and Novartis. Holds a doctorate in pharmaceutical technologies from the University of Pavia. These are source-dated career details; continued 2026 advisory tenure is not independently established.

Named to Sarcura’s advisory board in August 2024. His career includes product development at Sartorius and the CTO role at IntelliCyt. Holds a doctorate in microbiology and immunology from Creighton University. Continued 2026 tenure is not independently established by the dated appointment article.

Gertjan Bartlema is venture partner at Eckuity Capital. International biotechnology executive and Populus Bio co-founder. Populus’s own biography describes his Vico Therapeutics CEO position as previous, qualifying the older Eckuity headline.

Matt Luciw directs Neurala’s AI research, including efficient computer vision, industrial inspection and adaptive learning on constrained devices. He joined the company in 2014 after postdoctoral work at IDSIA in Switzerland and completed a PhD in computer science at Michigan State University. His research background includes numerous peer-reviewed publications and collaboration with engineering teams to bring machine learning into products.

Peter Greaney is venture partner at Eckuity Capital. Physician and WorkCare founder contributing occupational-health services experience. WorkCare’s own current directory calls him founder and chief medical officer; outside executive-chair claims are historical or unconfirmed.

Daniel Glasser is Neurala’s senior vice president of operations. His technology-delivery experience spans large companies, government agencies and startups. His current responsibilities cover operating plans, team development, revenue operations and commercial partnerships. He earned an MBA at Boston University’s Questrom School of Management.

Dan Curtis leads Neurala’s finance function. His published career spans public companies, venture-backed businesses and Big Four accounting, with experience in corporate transactions and operational finance. He previously served as CFO at Vitrue, Kova Solutions and SiteAdvisor, companies subsequently acquired by Oracle, Berkshire Hathaway and McAfee respectively. He earned an honors bachelor’s degree from Boston College. Fundraising totals in his career biography are not attributed as capital raised by Neurala.

Peter Cicala is venture partner at Eckuity Capital. Pharmaceutical intellectual-property strategist and former Celgene patent executive; contributes legal and commercialization expertise.

Elaine Pang is head of portfolio operations at Eckuity Capital. Coordinates portfolio operations, operational support and collaboration among Eckuity’s healthcare businesses.

Anatoli Gorchet is Neurala’s current co-founder, chief executive officer and chief technology officer. The company identifies him as the computational neuroscience architect of its Lifelong Deep Neural Network. He has over two decades of experience in parallel neural computing, including early application of GPUs to neural modeling. His background includes a PhD in Cognitive and Neural Systems at Boston University and a master’s degree in computer science. His public work includes neural network publications, patents and advising businesses on AI deployment. The company’s original named portrait uses the longer name Anatoly Gorshechnikov in its asset filename; this alias is retained as provenance rather than a second person.

Ken Eagle is cfo at Eckuity Capital. Listed as CFO in Eckuity’s current public directory, responsible for fund finance and reporting. Earlier legal filings separately name Jonny He; they are distinct people.

Paige Leonard’s public self-profile identifies SideBy Care as her current employer in the Denver/Boulder area. Her background includes Virginia Tech business education and communications work. She received a 2024 National Council for Mental Wellbeing advocacy award and Colorado Healthcare Communicators recognition. The specific current SideBy Care title is not visible in the accessible primary profile.

Anna Juarez, LPC, is a Louisiana mental-health counselor whose current self-profile identifies SideBy Care. She studied at the University of Louisiana at Lafayette Graduate School and previously worked as a journalist. Her self-submitted practitioner profile describes virtual counseling, anxiety, depression, trauma and EMDR. A dated practitioner directory’s provisional-license wording is not treated as a current regulator verification.

Heather Ames is a cognitive scientist and Neurala co-founder whose work helped translate neuroscience research into a commercial AI business. The company credits her with shaping its organizational and commercial foundations. Its present leadership directory lists her in the co-founder section and does not assign her a current executive operating title.

Ryan Green is coo & head of investor relations at Eckuity Capital. Oversees Eckuity’s operations and investor relationships, including fund administration and investor communications.

Angel Lewis, MA, LPC, is a licensed professional counselor whose current public self-profile identifies SideBy Care. Her own recent posts discuss the company’s gut–brain care programme and Unio Specialty Care partnership. Her accessible professional profile describes more than eight years of mental-health experience; the specific employer title and appointment date are not published.

Jason Criscione is operating partner at Eckuity Capital. Biomedical engineer and healthcare entrepreneur supporting portfolio development; founded Enquyst Technologies and earned a Yale biomedical-engineering PhD.

Max Versace, also known as Massimiliano Versace, is a neuroscientist and entrepreneur who co-founded Neurala and led its research commercialization and growth as CEO. His training includes doctoral study in cognitive and neural systems at Boston University and experimental psychology at the University of Trieste. His current own biography identifies subsequent leadership of Emergent AI at Analog Devices. Neurala now lists him among its co-founders, while its current CEO is Anatoli Gorchet. His earlier CEO title is retained as historical rather than current.

Sarah Volling, MS, RD, LDN, CDCES, is a registered dietitian whose current self-profile identifies SideBy Care. She also owns Eat Practical in Edwardsville, Illinois. Her own practitioner biography describes gastrointestinal nutrition and diabetes-care qualifications, with undergraduate training at Kansas State University and graduate training at Fontbonne University. Her employer-specific SideBy Care title is not visible in the accessible primary profile.

Neurala, Inc. is a Boston-based developer of brain-inspired vision AI for embedded and industrial products. Founded in 2006 by neuroscientists Max Versace, Heather Ames and Anatoli Gorchet, it commercialized research supported by NASA, DARPA and the US Air Force. Its patented Lifelong Deep Neural Network (L-DNN) uses complementary learning approaches inspired by the neocortex and hippocampus to support visual learning from limited examples and continued adaptation on edge devices. The current business licenses and integrates this technology into OEM hardware, software and manufacturing inspection systems; VIA is its industrial visual-inspection offering. The company publishes applications with FLIR, Sony Semiconductor Solutions and IHI, and identifies its headquarters at 308 Congress Street, Boston, Massachusetts 02210. A European subsidiary in Trieste is distinct from the Boston parent. The current public leadership directory identifies Anatoli Gorchet as co-founder, CEO and CTO; Max Versace is a co-founder and former CEO, with subsequent work at Analog Devices. Historical consumer robotics, drone and automotive applications are part of its development history. This company is distinct from Neurala Biosciences at neurala.co and Neura Robotics. Financing announcements establish separate $750,000 seed, $1.2 million follow-on, $14 million Series A and $12 million later financing events; cumulative fundraising figures are not additional rounds. Clinical treatment or regulatory clearance is not claimed for its industrial AI platform.

Jessica Person Eckert, MPH, RDN, LDN, is a registered dietitian based in Lafayette, Louisiana. Her public self-profile identifies SideBy Care as her current employer and her own posts describe working with its virtual care team. She studied at Tulane University. The employer-specific title is not visible in the accessible primary profile.

Ambre Millon is investment analyst at Eckuity Capital. Works on financial analysis, market research and transaction diligence; studied business management at Bayes Business School.

Waez Umer is investment analyst at Eckuity Capital. Combines medical training and investment analysis to evaluate healthcare businesses and monitor the portfolio.

Michael Salako is principal at Eckuity Capital. Evaluates and executes healthcare investments, drawing on biomedical engineering and venture-investment experience. Michael Salako was Start Codon senior investment associate in the Cambridge2020 report and investment director in2021–2024 primary partner/event publications. His Bristol speaker biography describes previous Cancer Research UK commercialisation, a biochemistry degree, molecular virology/toxicology PhD, MBA and immuno-oncology postdoctoral research. These historical Start Codon roles do not replace his preserved Eckuity affiliation; the same own-linked professional LinkedIn identity corroborates the match.

Karim Maasarani is general partner at Eckuity Capital. Leads portfolio operations and commercial development across Eckuity’s healthcare investments.

Victoria Manax Rutson is general partner at Eckuity Capital. Physician and life-sciences investor contributing oncology, clinical-development and healthcare commercialization experience.

Youssef Sebban is managing partner at Eckuity Capital. Founded Eckuity’s healthcare investment platform and leads its investment strategy and portfolio development.

Eckuity Capital is a healthcare growth-investment platform backing commercial-stage medical technology, healthcare software and life-sciences businesses. Its published strategy combines investment capital with commercialization support, including sales infrastructure, market access and the Nettwork Holdings operating platform. Relevant published exposure includes laboratory automation and AI at Automata, surgical data and AI at Caresyntax and FluidAI, digital-health software at Huma, genomic analytics at Sonrai Analytics, and investigational CNS drug-delivery technology at Enquyst. The manager’s portfolio descriptions are its own claims; they do not independently establish clinical accuracy, regulatory approval or investment cash amounts. The platform has two distinct legal advisers in current public filings: Eckuity LLC, CRD328867 / SEC802-129049 (March30,2026 ADV), manages the first fund and associated vehicles through Eckuity GP LLC; Eckuity Capital Management LLC, CRD341916 / SEC802-136192 (April3,2026 ADV), manages Eckuity Fund II LP through Eckuity GP II LLC. The single published commercial platform is recorded here with explicit fund-specific legal management, without asserting that these LLCs legally merged or renamed one another. Its February28,2024 own final-close announcement states USD155million in the body, despite a rounded USD150million headline; its own LP independently confirms USD155million. Fund II reached a first close announced June25,2026, with no disclosed amount, and began investing through the Automata Series C alongside Danaher. Current own directory publishes twelve staff, twelve venture partners and six advisory-board members. The June2026 announcement confirms Paul Enever and Alejandro Sanchez joined as partners following their Evidity work. Original Canepa/Evidity financing checks remain attributed to that historical manager; people joining or portfolio integration do not establish new Eckuity cash investments. Two additional officers are separately scoped to dated legal filings: Vishal Jain remains a managing partner of the first legal adviser as of March2026 but is absent the newer directory; Jonny He is the legal CFO in March/April filings, while the newer directory lists Ken Eagle as CFO. Exact transitions and end days are unknown. Sixteen actual private fund and SPV vehicles are recorded from the two ADVs; SPVs and the Cayman/NJIEF vehicles do not multiply the USD155million first-fund close. Gross asset values, targets, conditional NJEDA commitments, portfolio purchase headlines and contingent acquisition milestones are not closed fund cash.

Jeffrey R. Alvord is identified as a director and president of Omidyar Technology Ventures, LLC in Akili’s2022 SEC beneficial-ownership disclosure, which spells his given name Jeffery. Other official Omidyar-affiliated filings identify Jeffrey R./Jeffrey Robert Alvord. Current OTV tenure and a verified public portrait were not established.

Matthew K. Stepan is identified as a director and vice president of Omidyar Technology Ventures, LLC in Akili’s2022 SEC beneficial-ownership disclosure. Current OTV tenure and a verified public portrait were not established. No identity association with similarly named real-estate professionals is assumed.

Pierre Omidyar founded eBay and created and solely funded Omidyar Technology Ventures, according to its official archived website. The distinct Omidyar Network also identifies him as its co-founder. The OTV affiliation does not imply personal attribution of every portfolio check or a pooled investment fund close.

Robinson C. Jacobs is identified as a director and vice president of Omidyar Technology Ventures, LLC in Akili’s2022 SEC beneficial-ownership disclosure. Current OTV tenure and a verified public portrait were not established; this statutory affiliation is source-qualified as historical.

Pearl Chan, also publicly known as Pearl Chan Schopmeyer, joined the founding Omidyar Technology Ventures team in2015 and was its Principal in the2017 official directory. She previously worked at Omidyar Network, Goldman Sachs and Tinicum. Her own2019 account states she left the Omidyar group to build Snowball Wealth; the OTV role is historical.

Chris Bishko was a Partner at Omidyar Technology Ventures in its2017 official directory, following investment roles at Omidyar Network and JPMorgan. He studied biomedical engineering and English at Duke University. This is a historical OTV affiliation, not a claim of current employment.

Todor Tashev was Managing Partner of Omidyar Technology Ventures on its official archived public directory, including the January2021 homepage. He previously led global technology investments at Omidyar Network, worked on Tellme Networks mobile applications and made venture/private-equity investments at JPMorgan. His education includes Harvard Business School and Carleton University. Current OTV tenure is unconfirmed.

Omidyar Technology Ventures (OTV) is an early-stage technology investment firm created and solely funded by eBay founder Pierre Omidyar. Its official historical website describes backing founders tackling large markets and meaningful technical problems; its published portfolio includes artificial intelligence, enterprise software, cybersecurity, logistics and digital medicine, including Akili Interactive, Nervana Systems and Gamalon. Akili’s 2022 SEC filing identifies the investing legal entity as Omidyar Technology Ventures, LLC and names its statutory directors/officers. The archived public investment team includes Todor Tashev, Chris Bishko, Pearl Chan and Sid Trivedi; these affiliations are explicitly historical rather than a claim that all remain employees today. OTV is distinct from Omidyar Network and other Omidyar-affiliated entities. The official website no longer resolves as of October 7, 2026; current operating status and a complete current roster are not publicly verified, and this does not establish legal dissolution. No verified public pooled-fund close or fund corpus was found; Pierre Omidyar’s sole funding and portfolio investments are not invented LP fund commitments.

Norah (Cliff) Candito, MS, RDN, LDN, CLC, is a registered dietitian and Director of Clinical Operations at SideBy Care, as confirmed by her own Nutrition with Norah practitioner biography. She founded that practice, took it full-time in January2022 and focuses on gastrointestinal and hormonal health. She is based in Rhode Island and appeared with Sahil Patel in a primary SideBy Care clinical interview.

Pryon builds an enterprise AI memory layer that ingests and governs organizational knowledge so search applications and AI agents can retrieve answers from trusted content. Its ingestion, retrieval, and generation engines process text, images, audio, and video, connect to enterprise content sources, and return answers with source citations and access controls. Organizations can integrate it through APIs and deploy it in the cloud or on premises for uses including employee knowledge search, customer support, and government and industrial workflows.

Dan Judkins is a toy-design executive and co-founder of The AI Toy Company, formerly Magical Toys. The company names him Chief Product Officer in its Bondu launch press release and direct email interview.

Fateen Anam Rafid co-founded The AI Toy Company, formerly Magical Toys, which makes Bondu. He is named founder and CEO in its October 2025 issuer press release; the company’s April 2026 educational articles identify him as Fateen Anam, CEO at Bondu.

Igor Jablokov founded Pryon and is listed as its Chairman, CEO, and a director in its current leadership directory. He previously founded cloud speech-recognition company Yap, which Amazon acquired, and led multimodal and speech technology work at IBM.

Sahil R. Patel, MD, is co-founder and Chief Medical Officer of SideBy Care. The March2026 Unio Specialty Care partnership announcement identifies him as CMO; SideBy’s own 2026 presentation identifies the co-founder title. He is a gastroenterologist whose self-submitted Keystone GI Consultants clinical profile describes SideBy Care and lists board certification in gastroenterology and internal medicine. His medical education and residency are listed at St. George’s University and Drexel University.

SideBy Care, Inc. is a Boulder, Colorado virtual healthcare company focused on disorders of gut–brain interaction, including irritable bowel syndrome and functional digestive symptoms. Its Mind-Gut Program extends gastroenterology practices with coordinated behavioral health, registered-dietitian nutrition care and care advocacy through virtual visits. CEO and co-founder Patrick Leonard, co-founder and Chief Medical Officer Sahil R. Patel, MD, and Director of Clinical Operations Norah Candito are publicly identified leaders. The company describes AI-assisted clinical workflows and EHR integration; its December2025 founder interview described a personalized AI dietitian as a planned product rather than an established autonomous treatment. A March2026 Unio Specialty Care partnership verifies clinical delivery, while current company communications describe complementary behavioral and nutrition support for Crohn’s disease and ulcerative colitis alongside medical care. Patient-reported program results are company-reported outcomes, not independent randomized efficacy evidence. This is a healthcare service, with no verified drug or device marketing approval attributed to the programme. FirstMile Ventures lists SideBy Care in its investment portfolio; the financing amount, stage and date are undisclosed. Colorado’s official grant-recipient report confirms an Advanced Industries non-dilutive award, with disbursement unverified. Public leadership coverage does not establish a complete clinical-staff or board roster. Current Play Money member holdings also verify a platform-sponsored investment through a Clutch Capital series vehicle; the operating platform is distinct from the legal SPV, and its initial $250,000 offering target with zero sales is not assigned as SideBy Care cash.

Patrick Leonard is CEO and co-founder of SideBy Care, an AI-assisted virtual care company for disorders of gut–brain interaction. He previously led CVS Health Virtual Care products, served as CTO of iTriage and built Aetna Digital, and co-founded AI medical-documentation company Sopris Health. His direct December2025 founder interview confirms these roles.

Nina Kandilian is a director in First Citizens Innovation Banking’s investor-coverage team, focused on healthcare and life-science venture relationships. Her prior experience includes MassChallenge HealthTech, healthtech product marketing and strategy, and digital transformation at Mass General Brigham. She studied at Suffolk University and Babson College.

Alex Lennox-Miller is a lead research analyst in First Citizens Innovation Banking’s Market Insights group, covering life sciences and healthcare. His earlier roles include healthcare analysis at CB Insights, Chilmark Research and Beth Israel Lahey Health. He studied anthropology at UMass Boston and earned an MBA at Northeastern University. The current published title is used despite older senior-analytics wording in his page biography.

Andrew Pardo is a principal researcher in First Citizens Innovation Banking’s Market Insights group in San Francisco. He covers capital markets, fundraising and exits across innovation economies. His earlier work was in buy-side financial-sector equity research, and he studied accounting at Loyola Marymount University.

Jake Ledbetter is a senior researcher at First Citizens Innovation Banking working on private-equity and venture-capital research. Before joining SVB in 2022, he worked at Bella Research Group. He holds economics degrees from Duke University and the University of Alabama at Birmingham and is a CFA charterholder.

Eli Oftedal is a principal researcher in First Citizens Innovation Banking’s Market Insights group. He analyzes venture investment, fundraising and exits, with a particular interest in climate technology. His earlier experience includes clean-energy venture investing, and he studied ecosystem science, economics and liberal arts at Colorado State University.

Josh Pherigo is a principal researcher in the Market Insights group at First Citizens Innovation Banking. He produces research and data analysis covering the innovation economy and venture-capital ecosystem. The bank publishes him as an author of its current State of the Markets and healthcare reports.

Adam Tweedy leads life-science and healthcare investor coverage at First Citizens Innovation Banking. He previously led corporate-liquidity and fund-banking teams and works with sector investors on banking services and strategic relationships. His education includes graduate business study at Babson College.

Andy Tsao leads Global Gateway at First Citizens Innovation Banking, supporting emerging-market innovation businesses and their US expansion. His banking career includes international venture relationships, technology lending and establishing SVB’s UK office. He studied at Colgate University and Boston University.

All Aboard Fund is a climate technology venture co-investment manager helping promising technologies cross the financing gap between successful pilots and large-scale commercial deployment. It works with a coalition of specialist climate investors to back scale-ready companies alongside a lead investor on the same terms, using shared diligence rather than replacing the lead investor. Its portfolio includes Zanskar, which applies AI to geothermal discovery and development; Terra CO2, which makes low-carbon cementitious materials; and Antora Energy, which stores renewable electricity as industrial heat in carbon thermal batteries. The fund is distinct from the coalition’s member firms and their combined assets.

Cross-Border Impact Ventures is a Toronto impact venture capital firm investing in health technologies that improve outcomes for women, children and adolescents and strengthen health systems. It backs early-growth companies, primarily at Series A and B in North America and Europe, developing medical devices, diagnostics, therapeutics and AI-enabled digital health. The firm supports global commercialization and access in emerging and underserved markets, combining health-impact and gender analysis with investment management. Published holdings include AI fetal-ultrasound software Sonio, cardiac monitoring company Cardiosense, AI proteomics company Oxford Cancer Analytics, oncology software OncoLens and neonatal incubator developer mOm. It launched independently in 2021 after incubation with Grand Challenges Canada.

Adeline Boatin is named in CBIV’s current advisory directory. Her precise strategic-versus-scientific board assignment is not resolved by the accessible directory text; the generic advisory title preserves the disclosed affiliation without inferring employment.

Alyson J. McGregor is named in CBIV’s current advisory directory. The issuer’s original launch identifies her as a scientific adviser specializing in sex and gender differences in disease.

Annie Thériault is Managing Partner at Cross-Border Impact Ventures and an investor in inclusive health technology. She previously served as Chief Investment Officer at Grand Challenges Canada and has worked in venture capital, impact investing, royalty financing and capital markets strategies. She holds a management PhD from the Rotman School, is a CFA charterholder and holds the ICD.D designation.

Camille Zivré is included in All Aboard Investment Management Company’s published internal team. The presentation identifies her separate Exa Ventures principal role and earlier byFounders, Inventure and Korelya experience. The outside principal title is not assigned to All Aboard.

Chris Anderson is Co-founder and General Partner of All Aboard Fund and serves on its investment committee. The manager’s presentation identifies his TED, Exascale/Exa Ventures and Thorcon affiliations. This is the TED curator, not an inferred match to other people named Chris Anderson.

Published in CBIV’s current advisory directory. The issuer’s original launch identifies her as a strategic adviser with BabyCenter and Johnson & Johnson operating experience.

Dana Deardorff is named in CBIV’s current advisory directory. Her precise strategic-versus-scientific board assignment is not resolved by the accessible directory text; the generic advisory title preserves the disclosed affiliation without inferring employment.

Donna Parr is Managing Partner at CBIV, with more than 30 years of experience managing venture capital, growth equity and private debt portfolios. She previously managed the GrowthWorks Canadian Fund and Canadian Medical Discoveries Fund and worked at OMERS and CPP. CBIV identifies her as a director of Constellation Software and Topicus.com.

Femke Smeets leads emerging-market work at CBIV, drawing on close to 20 years in healthcare financing, business development, capacity building and impact management across Africa, Latin America, the US and Europe. Her experience includes health SME fund technical assistance, digital health and health insurance platforms, and healthcare project finance.

Guilherme Sant’Anna is named in CBIV’s current advisory directory. His precise strategic-versus-scientific board assignment is not resolved by the accessible directory text; the generic advisory title preserves the disclosed affiliation without inferring employment.

Hannah Sharpe works at the intersection of environment and health at CBIV. She previously advised the Municipality of Caledon on sustainability and climate resilience and led life science and strategy work at Heal Mary Technologies, an AI platform matching oncology patients to clinical trials. She holds a master’s in environment and sustainability and a biology degree from Western University.

Issy Gordon leads investments at CBIV. She spent five years at Salica Investments, formerly Hambro Perks, where she developed its healthcare strategy and worked with Daye, Peppy, Lindus Health, Suri and Theremia. Her earlier work includes Deloitte M&A and product and growth roles at Percent and Asset Vault. She holds a London Business School management master’s degree.

Jack Haynes is included in All Aboard Investment Management Company’s published internal team. The presentation identifies his separate role as Head of Investments at True North Institute and earlier experience at Marwyn and PwC. That outside title is not assigned to All Aboard.

Jay Dessy is CIO of All Aboard Fund, named in co-founder True North Institute’s current report and the manager’s own public appointment announcement. He previously worked at Graphyte, Breakthrough Energy Catalyst and Gates Ventures, scaling novel climate technology and first-of-a-kind infrastructure.

John Arnold is a fund adviser and investment committee member in All Aboard’s published strategy presentation. His philanthropic Arnold Ventures affiliation is separate from the venture fund manager.

Juanita Cortés is CFO at CBIV and a public accountant and auditor qualified in Mexico with more than 25 years of Canadian experience. Her work spans financial planning, audits, IPOs and M&A across private equity, nonprofits, SaaS, manufacturing and other sectors, with GAAP, US GAAP, IFRS and ASPE experience.

Published in CBIV’s current advisory directory. The issuer’s original launch identifies her as a strategic adviser and Grand Challenges Canada leader.

Marjorie Jenkins is named in CBIV’s current advisory directory; the issuer’s original launch identifies her as a scientific adviser with expertise in women’s health and sex and gender differences.

Mark Gallagher leads investor coverage and business development at First Citizens Innovation Banking. His career includes technology and life-science banking, corporate venture relationships and regional business development at SVB. He works with investors and venture firms on banking services and strategic connections.

Megan Dover is Partner and Co-founder of CBIV. Her experience spans impact investing, venture advisory, M&A, corporate strategy, finance and biomedical research. Before the firm’s launch she advised health technology companies and helped mobilize equity and non-dilutive funding. She holds an MBA from Rotman and an engineering degree from Queen’s specializing in biomedical research within chemical engineering.

Megan Wenrich is COO of All Aboard Fund, as named in co-founder True North Institute’s current year-in-review report. The manager’s November 2025 strategy presentation previously listed her as Head of Capital Formation.

Nigel Topping is a fund adviser and investment committee member in All Aboard’s published strategy presentation, which separately identifies his climate leadership affiliations.

Published in CBIV’s current advisory directory. The issuer’s original launch identifies her as a strategic adviser with global health and Becton Dickinson experience.

Published in CBIV’s current advisory directory. The issuer’s original launch identifies him as a strategic adviser with healthcare technology, strategy and commercialization experience.

Staffan Qvist is a General Partner of All Aboard Fund and investment committee member. The manager’s presentation identifies him as CEO of QuantifiedCarbon, founder of Deepsense and Managing Partner of Exa Ventures.

Stan Miranda is Co-founder and General Partner of All Aboard Fund. The manager’s investment presentation identifies him as lead manager and investment committee member. He founded True North Institute and Partners Capital.

Tasha Noronha manages partnerships and operations at CBIV. She previously supported operations and key funder relationships at Grand Challenges Canada Foundation and worked with the Every Woman Every Child Innovation Marketplace. She holds an international development studies degree from the University of Toronto.

Tove Lilliestierna is included in All Aboard Investment Management Company’s published internal team. The presentation identifies her separate Exa Ventures partner role and earlier Norrsken, Bain and Citi experience. The outside partner title is not assigned to All Aboard.

Tristan Varakuta is included in All Aboard Investment Management Company’s published internal team. The presentation identifies his separate role as Investment Associate at True North Institute and previous L.E.K. consulting experience. That outside title is not assigned to All Aboard.

Mike Tramack leads loan administration at First Citizens Innovation Banking and is a member of its commercial-bank leadership team. His team oversees underwriting, credit decisions and portfolio governance. His SVB career began in 1998; he holds degrees from Stonehill College and Boston College.

Marc Cadieux is president of First Citizens Innovation Banking, the current technology and healthcare banking division formerly branded Silicon Valley Bank. He joined SVB in 1992 and held senior credit and sales positions, including chief credit officer from 2013, before becoming commercial-bank president in 2023. He studied economics at Colby College. His current title is confirmed by the bank’s October 2026 launch announcement.

Megan Scheffel leads First Citizens Innovation Banking’s life-science and healthcare business and its nationwide sector team. Her innovation-finance career at SVB began in 1997 and includes international credit leadership and technology-banking roles. She studied business administration and finance at the University of Colorado Boulder.

First Citizens Innovation Banking is the technology and healthcare commercial-banking division of First-Citizens Bank & Trust Company. The division officially launched this name on 6 October 2026, replacing the post-acquisition Silicon Valley Bank Technology & Healthcare Banking division brand. First Citizens acquired the Silicon Valley Bridge Bank loan and deposit business effective 27 March 2023 following the original Silicon Valley Bank failure. This unit is a commercial lender and banking provider for startups and growth companies in artificial intelligence, enterprise software, frontier technology, life sciences and healthcare; its services include venture debt, working-capital finance, treasury and international banking. Marc Cadieux is its president. The separately launched First Citizens Fund Banking division serves private-equity and venture-capital firms and is not represented as this unit’s staff or independent VC fund. Positive Development names the bank’s then-SVB division and Pinegrove Venture Partners as lenders in an up-to-USD45 million growth facility announced 13 January 2026; fresh proceeds, drawn cash and lender-specific allocations are undisclosed. This unit is distinct from the failed pre-2023 Silicon Valley Bank, historical SVB Financial Group, SVB Capital, Pinegrove Venture Partners and their separately constituted credit funds. Bank assets, deposits, client funds and lending commitments are not closed LP fund capital. Published current leadership and sector/research staff are source-qualified; no exhaustive private employee directory or bank-wide parent roster is asserted.

Roy Beveridge is a physician and healthcare executive with former chief medical officer responsibilities at Humana. His authenticated portrait and physician biography are preserved from the Wharton Healthcare Management Alumni Association’s historical publication. Positive Development’s January2025 SEC filing lists him as a director; that filing does not establish his present issuer board status.

Mark Pacala is a healthcare operating and private-equity advisor, published by National Partners in Healthcare as its chairman. His experience includes executive roles at American WholeHealth and the Forum Group, and investment work at Essex Woodlands. He holds degrees from Hamilton College and Harvard Business School. Positive Development’s January2025 SEC filing reports his directorship; current issuer board status is unverified.

Nick Whitehead, also published by B Capital as Nicholas Whitehead, is a Senior Principal focusing on early-stage investments. He previously supported the firm’s platform and capital-formation activities and worked at RBS and Houlihan Lokey. He holds an MBA from Columbia and an economics degree from Wharton. Positive Development’s January2025 SEC disclosure names him as a director; current issuer board status is not separately published. Current primary B Capital biography reviewed October8,2026: Our Team Nick Whitehead Senior Principal Function: Investment Location: Americas - San Francisco Stage: Early Stage, Growth Stage Expertise: Healthcare LinkedIn Nick Whitehead is a Senior Principal at B Capital, where he focuses on early-stage investments. Before transitioning to his current role, Nick worked on B Capital’s Platform team, supporting Capital Formation and follow-on fundraising for the portfolio. Prior to joining B Capital, he worked in investment banking at RBS in Hong Kong and the Financial Institutions Group at Houlihan Lokey in New York. He later founded a healthcare technology company and launched a consulting business advising early-stage startups on finance, fundraising and operations. Nick holds an MBA from Columbia Business School and a B.S. in Economics from the Wharton School at the University of Pennsylvania. He is based in San Francisco. Related Content 1/3 Article | Why We Invested Why We Invested: Flourish Health July 30, 2026 By: Adam Seabrook, Nick Whitehead and Athena Shea   B Capital is thrilled to announce its investment in Flourish Health,… Learn More → 2/3 Article | Why We Invested Why We Invested: Cadence June 25, 2026 By: Robert Mittendorff, MD, Adam Seabrook, Nick Whitehead, Athena Shea, and Keegan McGuire   B Capital is proud to partner… Learn More → 3/3 Article | Why We Invested Why We Invested: Innovaccer December 15, 2021 Author: Nick Whitehead; co-contributor Shwan Kazzaz The US healthcare market represents approximately 18% of GDP, and yet while spend has increased… Learn More →

Adam Seabrook is a B Capital partner investing in healthcare and digital health. His experience includes Hyde Park Angels and healthcare startup Imaging Advantage. He holds an MBA from the University of Chicago and an engineering bachelor’s degree from Cornell. B Capital’s own biography documents his Positive Development board service. Current primary B Capital biography reviewed October8,2026: Adam Seabrook is a Partner at B Capital leading the firm’s investments in Healthcare and Digital Health. Prior to joining B Capital, Adam worked at Hyde Park Angels, one of the largest angel networks in the United States. At B Capital, he has invested in and served on the board of companies such as Positive Development, Synapticure, Atomwise, Evidation, Sift Healthcare and PicnicHealth, among others. Adam was an early employee at Imaging Advantage, a teleradiology startup recently acquired by Envision Healthcare, where he managed implementation at hospitals around the United States, led workflow optimization efforts and helped acquire physician practices as part of a rollup strategy. As a result of a proposal Adam co-wrote to the Centers for Medicare & Medicaid Services, the company was awarded $6 million to develop a decision support tool for physicians. Adam was recently named to GrowthCap’s Top 40 Under 40 Growth Investors . Adam earned an MBA from the University of Chicago and a BS in Mechanical and Biomedical Engineering from Cornell University. He is based in Los Angeles.

Tomer Berkovitz is a Managing Partner at aMoon. He joined in2018 after roles in healthcare finance at J.P.Morgan and as Alcobra’s CFO and COO. He holds a finance PhD from Columbia. Positive Development announced his board appointment with its August2025 SeriesC financing. Tomer Berkovitz is published by aMoon as Managing Partner. Healthcare finance specialist who joined in2018 after J.P.Morgan investment banking and Alcobra executive roles.

Jon Pardew is a healthcare strategic advisor and former President and CEO of CCRM Fertility. Previously he led healthcare investment-banking work at St. Charles Capital. Positive Development appointed him to its board effective May1,2026. Its announcement also identifies Healix and Oula Health board service. An authenticated individual portrait was not retrieved.

Alisa Bahl is a clinical psychologist and President of The Bahl Group. Her career includes behavioral-health operations and payer strategy, formerly as Magellan Health’s chief strategy and innovation officer and Optum Health’s senior vice president of clinical solutions. Positive Development appointed her to its board effective May1,2026.

Jumpspace Ventures is an early-stage neurotechnology investor focused on brain-computer interfaces and devices that record from or stimulate the brain and nervous system. It backs neural diagnostics, neuromodulation and medical-device companies addressing neurological conditions and human-machine interaction. It operates a publicly listed AngelList syndicate and deal-specific legal investment vehicles.

Serendipity Impact VC invests in early-stage technology addressing mental, neurological and behavioral health. Its partners help founders translate scientific advances into products, clinical and regulatory plans, customer adoption and scalable businesses, connecting Israeli innovation with the U.S. market. Its legal manager is Serendipity Impact VC, LLC.

Previously co-founded ID8 Investments, Facteus and Artisan Council and worked in investment banking at Morgan Stanley.

Founder of TOBO.CREATIVE, with marketing and startup growth experience.

Neurotechnology entrepreneur who founded surgical visualization company Visionsense and previously led Joy Ventures.

Medtech commercial strategist and former Visionsense commercial leader.

Behavioral scientist and founding director of the YU Innovation Lab, with U.S. commercialization experience.

Investor and entrepreneur working across health innovation and mental-health capital.

David (Dave) Baszucki is the founder and CEO of Roblox. Roblox’s own leadership biography identifies his earlier founding of Knowledge Revolution and its Interactive Physics software, subsequent sale to MSC Software, and Stanford University electrical-engineering education. Akili’s May26,2021 financing announcement explicitly names Dave Baszucki, founder and CEO of Roblox, as an individual investor in its USD110M SeriesD. This is a personal investment attribution; it does not establish a Roblox corporate investment, an Akili board appointment, or an individual ticket amount.

Josh Feder is Executive Medical Director at Positive Development, according to the company’s current public directory. The company publishes the credentials MD. The company provides developmental relationship-based autism care integrating clinical disciplines and family support. A longer individual biography is not published in this directory.

Partha Boocha is Chief Technology Officer at Positive Development, according to the company’s current public directory. The company provides developmental relationship-based autism care integrating clinical disciplines and family support. A longer individual biography is not published in this directory.

Paul Bohlander is Chief Product Officer at Positive Development, according to the company’s current public directory. The company provides developmental relationship-based autism care integrating clinical disciplines and family support. A longer individual biography is not published in this directory.

Kate Rollins is Chief Clinical Officer at Positive Development, according to the company’s current public directory. The company publishes the credentials MSN, RN. The company provides developmental relationship-based autism care integrating clinical disciplines and family support. A longer individual biography is not published in this directory.

Greg Fuller is Chief Operating Officer at Positive Development, according to the company’s current public directory. The company provides developmental relationship-based autism care integrating clinical disciplines and family support. A longer individual biography is not published in this directory.

Chad Pomeroy is President at Positive Development, according to the company’s current public directory. The company provides developmental relationship-based autism care integrating clinical disciplines and family support. A longer individual biography is not published in this directory.

John Banta is Co-founder & Executive Chairman at Positive Development, according to the company’s current public directory. The company provides developmental relationship-based autism care integrating clinical disciplines and family support. A longer individual biography is not published in this directory.

Mike Suiters is Co-founder & Chief Executive Officer at Positive Development, according to the company’s current public directory. The company provides developmental relationship-based autism care integrating clinical disciplines and family support. A longer individual biography is not published in this directory.

Lauren Svymbersky is Clinical Director (Metro East Area, IL) at Positive Development, according to the company’s current public directory. The company publishes the credentials MA, CCC-SLP. The company provides developmental relationship-based autism care integrating clinical disciplines and family support. A longer individual biography is not published in this directory.

London-based early-stage venture capital firm investing in technology companies that improve health, make society more inclusive or address environmental problems. Its Tech for Good programme combines initial equity investment with founder support, and it makes follow-on investments from pre-seed through Series A and B. Its portfolio includes healthcare software, accessibility technology, sustainable hardware and enterprise software; impact and commercial growth are central to its investment approach.

Northern UK investment group formed from Par Equity and Praetura in 2025. Through PXN Ventures and PXN Investments it backs businesses from pre-seed to growth, combining venture capital with operational support and tax-efficient investment products. Its strategies include enterprise software, AI, deep technology, healthcare and life sciences, industrial and climate technologies, and natural capital. Regulated subsidiaries include Par Fund Management and the Praetura/PXN asset-management business; predecessor funds retain their original identities.

Mental-health social worker and S12 Solutions co-founder; supports health innovation.

Par Equity founding partner and investment-committee member; also a PXN Group partner.

Finance and fund-valuation specialist, previously at Deliveroo and EY.

Impact-investing and founder-origination professional with ESG and human-rights experience.

Media and technology strategy professional with executive and nonexecutive board experience.

Revenue and go-to-market specialist supporting seed and Series A companies.

Product designer supporting founders with prototyping, development and product launches.

Early-stage investor experienced in commercial growth, fundraising and impact strategy.

Startup-support specialist working on fundraising, product testing and portfolio development.

BGV co-founder and CEO; previously founded School of Everything.

Investor-relations and operations professional formerly at IBM and Octopus Ventures.

Independent investment-committee chair with private-equity and venture-capital experience.

Susan Smith-Foley is Clinical Director (Cherry Hill, NJ; Lakewood, NJ) at Positive Development, according to the company’s current public directory. The company publishes the credentials OTD, MPA, OTR/L. The company provides developmental relationship-based autism care integrating clinical disciplines and family support. A longer individual biography is not published in this directory.

Enterprise technology leader experienced in sales, commercial strategy and growth.

Growth investor at Mobeus and former Beringea chief investment officer.

Design and social-impact adviser who co-founded accessible-navigation company Wayfindr.

Founder-selection and fund-operations specialist with corporate innovation experience.

Alexandra Smith is Clinical Director (Broken Arrow, OK; Tulsa, OK) at Positive Development, according to the company’s current public directory. The company publishes the credentials MS, OTR/L. The company provides developmental relationship-based autism care integrating clinical disciplines and family support. A longer individual biography is not published in this directory.

Ben Russell is Clinical Director (Long Beach, CA; Whittier, CA) at Positive Development, according to the company’s current public directory. The company publishes the credentials PsyD. The company provides developmental relationship-based autism care integrating clinical disciplines and family support. A longer individual biography is not published in this directory.

Lina Moyano is Clinical Director (Fort Lauderdale, FL) at Positive Development, according to the company’s current public directory. The company publishes the credentials EdD, LCSW. The company provides developmental relationship-based autism care integrating clinical disciplines and family support. A longer individual biography is not published in this directory.

Liesl Hartmann is Clinical Director (Bethesda, MD; Capitol Hill, DC; Merrifield, VA) at Positive Development, according to the company’s current public directory. The company publishes the credentials MA, CCC-SLP, BCS-CL. The company provides developmental relationship-based autism care integrating clinical disciplines and family support. A longer individual biography is not published in this directory.

Cindy Davis is Clinical Director (Culver City, CA; Northridge, CA; Pasadena, CA) at Positive Development, according to the company’s current public directory. The company publishes the credentials PhD. The company provides developmental relationship-based autism care integrating clinical disciplines and family support. A longer individual biography is not published in this directory.

Positive Development, Inc. is a Delaware neurodevelopmental care company incorporated in 2020. It provides developmental relationship-based interventions for autistic children and their families, integrating speech-language, occupational and mental-health therapy with parent coaching through in-home and center-based care. Its own materials describe proprietary data and AI-enabled tools supporting care delivery, operations and family experience. Claims about clinical outcomes, cost reductions and program reach are issuer-reported rather than independently validated here. The current public directory identifies clinical directors and corporate leadership, including co-founder and CEO Mike Suiters and executive chairman John Banta. Verified primary disclosures include a cumulatively amended 2020–2021 equity offering, a fully sold 2022 offering, securities sold in a 2024 financing, a closed USD51.5M Series C announced in August2025, and a closed January2026 credit facility with up to USD45M capacity. The last figure is available credit capacity, not disclosed funded cash. Payer partnerships are not automatically investment relationships.

LVIS Corporation is a Palo Alto neurotechnology company founded in2013 by Stanford neuroscientist and electrical engineer Jin Hyung Lee. It develops NeuroMatch, a cloud-based EEG review and analysis platform using neural information analysis, AI and brain-network visualisation to support qualified medical practitioners. Its current website lists offices in Palo Alto, Gangnam/Seoul and Daegu, and exclusive technology licences from UCLA and Stanford. FDA510(k) clearances K222450, K241390 and K250239 concern NeuroMatch, a ClassII electroencephalograph software device. The latest K250239 covers adult patients18years and older, artifact reduction, seizure/spike detection and source localisation; the software does not replace real-time EEG monitoring or the physician’s interpretation. These device-specific clearances do not establish approval of every advertised future neurological diagnostic or therapeutic feature. The issuer states that some features are not cleared for USuse. A primary January11,2022 SKNetworks announcement confirms participation in an announced USD15million SeriesB-2, and distinguishes SKInc.’s earlier2018 investment. A&E Investments independently confirms an investment relationship with the exact company. Neither academic research grants nor portfolio-card dates are treated as corporate financing cash. LVIS is distinct from MicroVention’s LVIS intracranial stent and the separate Neuromatch educational nonprofit.

Bill Antilla is a healthcare executive with a current publicly disclosed LVIS affiliation in Palo Alto. His own profile describes a background in neurology and sleep-diagnostic medical devices, including EEG, polysomnography and ambulatory EEG product development. The primary2023 FDAK222450 record names WilliamAntilla as LVIS’s applicant contact, distinguished from external consultant Veranex correspondent ZaneLiu. His current accessible profile confirms LVIS but does not expose his exact executive title; third-party product-strategy titles are not substituted as current primary evidence. His public projects include EasyAmbulatory2 and EasyII/III EEG systems developed before the current LVIS product.

Jin Hyung Lee is the founder of LVIS Corporation, which her company states she established in Palo Alto in2013. She is an associate professor of neurology and neurological sciences, neurosurgery and bioengineering at Stanford, with a courtesy appointment in electrical engineering. Her laboratory develops interdisciplinary methods to analyse, visualise and control systems-level neural circuits using biology, engineering, imaging and signal processing. She holds an electrical engineering bachelor’s degree from Seoul National University and master’s and doctoral degrees from Stanford, completing the PhD in2004. Stanford lists her NIHDirector’s Pioneer Award in2019. SKNetworks’2022 primary announcement also identified her as LVISCEO; the current company website confirms founder capacity without a complete executive roster. Her academic research awards are distinct from corporate fundraising.

Ryan Park is named among LVIS’s public company employee listings, with the company’s own directory linking his exact professional profile at ryan-investor. This establishes the published LVIS affiliation; the accessible primary material does not establish his exact operating position, board capacity, educational history or appointment dates. No investment-manager role or personal investment is inferred from his profile slug. Other RyanPark namesakes remain distinct.

Samuel Lee is a publicly listed LVIS team member, confirmed by the company’s own employee directory and his exact self-authored professional profile. His profile identifies Alameda, California and the University of California,Davis, and describes professional learning in AI-assisted financial forecasting and MicrosoftCopilot. The accessible primary profile does not disclose his exact LVISjob title or appointment dates; a third-party chief-financial-officer label is not imported as a confirmed current executive capacity. He is distinct from similarly named finance, recruiting and software professionals at other employers.

Sweta Srivastava is LVISCorporation’s head of regulatory affairs, explicitly named as the applicant contact in the primary NeuroMatch K241390 and K250239 FDA510(k) summaries. Her own current public profile and LVIS’s own employee directory corroborate the company affiliation. Her public professional background includes medical-device regulatory strategy, quality and healthcare consulting; she studied at the University of Southern California and holds Regulatory Affairs Certification for devices from RAPS, issued in2024. Exact company appointment dates are undisclosed. She is distinguished from unrelated educators and similarly named professionals.

Kaitlyn (Kait) Tregenza is named as an adviser on Emmeline Ventures’ current website. Its biography describes early-stage venture experience across several countries, climate and sustainability work, and a current focus on women’s and sexual health. An exact appointment date or specific investment vehicle is undisclosed.

Gary Fraser is named as an adviser on Emmeline Ventures’ current website. Its biography describes MBA-program leadership at UCLA Anderson, adjunct teaching at NYU Stern and previous brand-management work. It identifies a University of Pennsylvania EdD. These outside academic affiliations are distinct from employment at the venture manager.

Senofer Mendoza is an adviser to Emmeline Ventures according to its current public directory. The issuer biography also identifies her as a founder and general partner of Mendoza Ventures, focused on fintech, artificial intelligence and cybersecurity. Her outside manager role does not imply an Emmeline fund allocation, personal portfolio check or LP investment.

Naseem Sayani co-founded Emmeline Ventures and formerly served as a general partner. The current firm website labels her Co-Founder, while the 2026 UCSF RISE UP speaker biography describes her Emmeline founding-partner role in the past tense and the September2026 first-hand interview explicitly calls her a previous GP. That interview identifies current GCWC and GCWC Capital founder/CEO work. Current Emmeline GP status and an exact departure day are not inferred from older team biographies or SEC filings.

Azin Radsan van Alebeek co-founded Emmeline Ventures and is a current general partner. Her company biography describes executive, board-advisory and educational work across the United States and Europe, with an interest in women’s financial independence. The July2025 Fund I SEC filing names Azin van Alebeek as an executive officer.

contextflow develops deep-learning software that helps radiologists analyze chest CT scans for suspected lung cancer, interstitial lung disease and COPD. Its ADVANCE Chest CT platform detects and measures pulmonary nodules, tracks them across follow-up scans, quantifies lung tissue abnormalities, assesses incidental coronary artery calcium and retrieves comparable imaging cases within radiologists’ existing viewers. Its broader solution suite integrates RevealAI-Lung nodule risk assessment and CINA-iPE pulmonary embolism detection. Founded as a Medical University of Vienna spinout, contextflow GmbH became part of 4DMedical’s European expansion in 2026; 4DMedical describes the acquisition as completed in its August 3, 2026 publication.

Methinks AI develops medical imaging software that helps hospital teams triage acute stroke patients. Its NCCT Stroke software analyzes non-contrast head CT scans for suspected large-vessel occlusions and intracerebral hemorrhages; CTA Stroke analyzes CT angiography for suspected large-vessel occlusions. The software sends alerts and imaging results through Microsoft Teams and integrates with hospital imaging workflows to support coordination between clinicians, transfers and treatment decisions. The Barcelona company operates legally as Methinks Software S.L.

Methinks’ current team page identifies him as Senior Finance Manager in a named employee testimonial. He says he joined the company in January 2023 after consulting for European technology startups.

Marc Ribó is named on Anaconda Biomed’s current public scientific advisory board. The issuer describes the clinician’s external clinical affiliation as Assistant Professor Stroke Unit. Department of Neurology Neurologist. Hospital Vall d’Hebron. Barcelona Professor of Neurology at U.A.B Editor, Interventional Neurology Journal. This is an advisory relationship rather than company employment.

Tudor Jovin is named on Anaconda Biomed’s current public scientific advisory board. The issuer describes the clinician’s external clinical affiliation as Medical Director, Neuroscience Service Line, Professor and Chair, Department of Neurology, Cooper University Health Care, Camden, New Jersey. Past President, Society of Vascular and Interventional Neurology (SVIN). This is an advisory relationship rather than company employment.

Stephanie Greer co-founded Akin Mental Health and held Doro Mind’s Director of Product Management role when announcing Akin’s integration in2024. The current company’s public2026 farewell states she has departed to train as a marriage and family therapist, so this role is historical. Her older Akin biography describes a neuroscience doctorate at Berkeley and digital-health product work at Apple and Hopelab.

Brady Richards co-founded Doro Mind, drawing on healthcare software-building experience and family experience of serious mental illness. The company publishes him alongside Mimi Liu as co-CEO. SEC filings also name Francis Brady Richards as an executive officer and director.

Dr. John Mackenzie, DNP, MAOL, FNP, RN, a retired member of the Armed Forces, is a nurse practitioner at Doro Mind, where he brings decades of leadership in behavioral health as a psychiatric nurse, supervisor, and interim inpatient director. Doro Mind’s terms distinguish clinical-provider services from the company’s support platform; a published provider-team affiliation does not establish payroll employment.

Mimi Liu co-founded Doro Mind to improve family support and continuity of care for people living with serious mental illness. Her published founder story describes lived family experience guiding the company’s approach.

Dr. Shayna Feuer, DNP, MSN, RN is a nurse practitioner at Doro Mind, where she brings her experience as a board-certified psychiatric nurse practitioner specializing in integrative, evidence-based care for individuals across the lifespan. Doro Mind’s terms distinguish clinical-provider services from the company’s support platform; a published provider-team affiliation does not establish payroll employment.

Clare Jibb, MSN, PMHNP-BC is a nurse practitioner at Doro Mind, where she brings decades of experience in psychiatric care, both in the U.S. and the U.K., to her work with individuals and families facing serious mental illness. Doro Mind’s terms distinguish clinical-provider services from the company’s support platform; a published provider-team affiliation does not establish payroll employment.

Dr. Hannah Bock, DNP, PMHNP-BC is the Associate Clinical Director at Doro Mind, where she leads with both clinical insight and strategic focus. As a psychiatric nurse practitioner, Hannah provides direct care to individuals and families navigating serious mental illness, combining deep empathy with medical precision. Doro Mind’s terms distinguish clinical-provider services from the company’s support platform; a published provider-team affiliation does not establish payroll employment.

Dr. Robert Laitman is a pioneering physician in psychiatric internal medicine and the Founding Clinical Director at Doro Mind. He is nationally recognized for his leadership in treating serious mental illness with evidence-based, compassionate care, shaped by both decades of clinical expertise and his lived experience as a father of a son diagnosed with schizophrenia. Doro Mind’s terms distinguish clinical-provider services from the company’s support platform; a published provider-team affiliation does not establish payroll employment.

Doro Mind Inc. is a private Delaware public-benefit company offering a technology-enabled care and family-support platform for people affected by schizophrenia, psychosis and related serious mental illnesses. Co-founders and co-CEOs Mimi Liu and Brady Richards combine healthcare software experience with lived family experience; the current published clinical-provider team is led by Founding Clinical Director Robert Laitman and Associate Clinical Director Hannah Bock. Doro Care provides access to specialized clinical treatment alongside family guidance, while Doro Compass supports navigation, coordination and existing care teams. The company’s legal terms distinguish its support platform from licensed provider services; named clinicians are recorded as published clinical-provider team members without asserting payroll employment. Its neuroscience and AI relevance includes an NIH/NIDA-funded research project developing coordinated-specialty-care interfaces and large-language-model role-play to help families prepare for clinical appointments. That project is feasibility-stage research, not proof that an AI treatment is clinically effective. Current website recovery and hospitalization percentages are company-reported promotional metrics, not independently established results. SEC filings identify exact Doro Mind Inc., CIK2008487, incorporated2023, with USD2,765,000 equity sold disclosedJanuary2024 and USD4,674,990 sold disclosedMarch2026; primary sources do not name priced-round stages or all buyers. An actual USD398,580 NIDA SBIR award in2026 is recorded separately from equity. Coalition Operators, SignalFire and City Light publish Doro as a portfolio company; those sources do not allocate checks to the two specific offerings. Akin Mental Health, incorporated2021 by Stephanie Greer and Matthew Montañez, later joined Doro; its earlier funding and team are not automatically Doro’s founding or cash history. Greer’s Doro product role is preserved historically because the issuer’s2026 farewell confirms her departure.

La Keisha Landrum Pierre co-founded Emmeline Ventures and is a current general partner. Her company biography describes international operating leadership and previous CEO, COO and chairwoman roles at a media company. Emmeline Ventures Fund I’s July2025 SEC filing lists La Keisha Pierre as an executive officer, supporting the same founder identity.

Emmeline Ventures is the female-founded US early-stage venture manager operating at emmelineventures.vc, launched in 2022 by La Keisha Landrum Pierre, Azin Radsan van Alebeek and Naseem Sayani. It backs female and female-identifying founders whose businesses help women manage health, build wealth or live in a cleaner, safer world, primarily at pre-seed and seed stages. Its current published roster includes general partners Pierre and van Alebeek, co-founder Sayani and advisers Gary Fraser, Senofer Mendoza and Kaitlyn Tregenza. Sayani’s GP role is historical: 2026 primary speaker and interview sources describe her as a former Emmeline partner, so older GP labels are not treated as current. Relevant investments include Flowly’s VR and biofeedback platform, Malloc and Wabbi cybersecurity, Ema’s women’s-health AI at emaapp.co, and diagnostics and healthcare companies AOA Dx, Infiuss Health and Relavo. Ema’s women’s-health identity is distinct from unrelated enterprise AI companies using the same name. The manager’s own investment disclosure separates fourteen Pilot Fund portfolio entries from twelve Fund I entries. The Pilot Fund refers to earlier investment vehicles owned exclusively by its general partners, rather than a verified single outside-LP legal fund or a specific Flowly financing round. Historical portfolio affiliation does not establish that every investment remains held today. Emmeline Ventures Fund I, LP is a distinct Delaware legal fund with SEC CIK 1915951. Its 11 July 2025 amendment reports USD 5,943,500 sold in an indefinite offering, with first sale 1 June 2022; earlier filings are snapshots of the same vehicle, not extra funds or amounts to sum. Associated entities named in the filing include Emmeline Ventures GP I, LLC and Goddess Pack Ventures Management, LLC. The sold figure is a dated exempt-offering snapshot, not a verified final-close amount, target or total global assets under management. Broader fundraising targets and reports that fundraising was nearing close are not entered as closed cash. The pilot portfolio’s aggregate cash size and exact legal vehicles remain undisclosed.

Experienced in research-based intellectual property, business development, licensing, trade sales and company turnarounds.

Adviser with international business-development and corporate-finance experience, including public listings and mergers and acquisitions.

Insight Partners source, reviewed October 8, 2026: Teddie Wardi joined Insight in 2017, sits on the firm's Investment Committee, and leads a team focused on early-growth investments in fast-growing software businesses. His investments include Wiz (acquired by Google), Armis Security, Hinge Health, SentinelOne, Atlan, Island, Cognigy, Docker, and many others. Previously, Teddie was a Partner at Atomico, a major European venture fund, where he led growth investments in SaaS companies. Prior to Atomico, he was with Dawn Capital, focusing on early-stage SaaS investments. Earlier in his career, Teddie co-founded Nervogrid, a cloud marketplace platform acquired by ALSO Group. Teddie holds an MBA from Harvard Business School and a B.Sc. from Aalto University in Helsinki.

Pharmacologist with preclinical and clinical drug-development experience and a background commercializing biotechnology projects.

Finance executive experienced in commercialization, restructuring, mergers and acquisitions, including previous roles at NORCE, TTS and EY.

Applied physicist with research, engineering and international software-business management experience.